Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Get Free Report) shares dropped 1.4% during trading on Tuesday . The stock traded as low as $3.47 and last traded at $3.50. Approximately 25,652 shares changed hands during trading, a decline of 6% from the average daily volume of 27,263 shares. The stock had previously closed at $3.55.
Lakeshore Biopharma Stock Performance
The business has a 50-day moving average of $2.81. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.13 and a quick ratio of 0.87.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. FMR LLC purchased a new stake in shares of Lakeshore Biopharma during the third quarter worth approximately $803,000. Hhlr Advisors LTD. purchased a new position in Lakeshore Biopharma in the 3rd quarter valued at $513,000. Finally, Barclays PLC acquired a new position in Lakeshore Biopharma in the 3rd quarter valued at $169,000. 52.64% of the stock is currently owned by institutional investors and hedge funds.
About Lakeshore Biopharma
LakeShore Biopharma Co, Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
See Also
- Five stocks we like better than Lakeshore Biopharma
- Canadian Penny Stocks: Can They Make You Rich?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- How to Calculate Inflation Rate
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Lakeshore Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakeshore Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.